Tarsus Pharmaceuticals (TARS) Income towards Parent Company (2019 - 2026)

Tarsus Pharmaceuticals' Income towards Parent Company history runs 8 years deep, the most recent figure standing at -$6.9 million for Q1 2026.

• In Q1 2026, Income towards Parent Company rose 72.52% year-over-year to -$6.9 million; the TTM figure through Mar 2026 stood at -$46.0 million (up 55.3% YoY), while the FY2025 annual figure was -$66.4 million, up 42.52% from the prior year.
• Income towards Parent Company was -$6.9 million for Q1 2026 at Tarsus Pharmaceuticals, down from -$6.2 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$5.5 million in Q2 2022 to a low of -$42.5 million in Q4 2023.
• Historically, Income towards Parent Company has averaged -$22.5 million across 5 years, with a median of -$23.1 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Income towards Parent Company slumped 474.12% in 2023, then soared 72.97% in 2025.
• A 5-year view of Income towards Parent Company shows it stood at -$13.6 million in 2022, then slumped by 211.62% to -$42.5 million in 2023, then surged by 45.63% to -$23.1 million in 2024, then surged by 72.97% to -$6.2 million in 2025, then dropped by 10.26% to -$6.9 million in 2026.
• The last three Income towards Parent Company figures came in at -$6.9 million (Q1 2026), -$6.2 million (Q4 2025), and -$12.7 million (Q3 2025), per Business Quant data.